A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine
This is an open label Phase II trial using pemetrexed as second-line treatment in patients
with advanced pancreatic cancer progressing within six months of prior gemcitabine-based
therapy. Subjects will receive pemetrexed 500 mg/m2 IV every 21 days until disease
progression or unacceptable toxicity.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
6 months after last patient enrolled
Jimmy J Hwang, M.D.
United States: Institutional Review Board
|Georgetown University Hospital/Lombardi Cancer Center||Washington, District of Columbia 20007|